Last updated: May 26, 2026
ERTAPENEM SODIUM supply is dominated by a small set of global manufacturers for the active pharmaceutical ingredient (API) and contract finished-dose production for branded and generic injectable erapenem products. Supply risk concentrates around sterile, lyophilized or solution-filled manufacturing capacity and around API routes (beta-lactam intermediates and thienamycin-derived chemistry).
Because “supplier” can mean API, finished dosage, or distributors, the supplier set is best understood by supply-chain tier.
Who supplies ertapenem sodium API and finished injectable products?
Featured snippet answer: Key suppliers of ertapenem sodium API and finished injectable products are concentrated in global generic injectables producers and specialty beta-lactam API players. Finished-dose supply is typically handled by contract sterile manufacturing organizations (CMOs) working for branded holders and generic NDA/ANDA manufacturers.
What counts as “suppliers” in the ertapenem sodium supply chain?
- API manufacturers: make ertapenem sodium (or upstream intermediates converted to API).
- Finished-dose manufacturers: produce sterile injectable vials (often lyophilized ertapenem sodium for reconstitution).
- License holders / ANDA filers: commercial marketers who source API and contract manufacturing.
- Wholesalers and distributors: purchase from manufacturers and distribute to hospitals and clinics.
Which companies are the typical ertapenem sodium API suppliers?
Featured snippet answer: API sourcing is usually shared across multiple ANDA programs, but API is not always listed publicly by manufacturer on product labels. The most reliable public mapping comes from regulatory product submissions, label/manufacturer lines, and procurement disclosures.
API supply concentration drivers
- Beta-lactam process controls: strict contamination control for penicillin-class chemistry.
- Sterility-adjacent manufacturing: even when API is non-sterile, downstream sterile fill-finish requires tight supply chain qualification.
- Regulatory change management: late-stage process changes to API or intermediates can trigger comparability work and re-approvals.
Which companies supply finished ertapenem sodium injection (vials)?
Featured snippet answer: Finished products are typically supplied by the same set of manufacturers that hold ANDAs for ertapenem sodium injection or operate as CMOs for ANDA holders.
Finished-dose “supplier” mapping (what to look for)
- Label “manufactured for / distributed by” lines (package insert and carton labeling).
- NDC-to-labeler mapping (brand owner or ANDA applicant).
- Site of manufacture (often listed as a specific sterile plant address on labeling).
What are the main global supplier regions for ertapenem sodium?
Featured snippet answer: Production is concentrated in North America, Europe, and Asia, with sterile fill-finish and final packaging capacity often in the US or in GMP-licensed plants in Europe and Asia.
North America
- US market demand pulls on both branded supply and ANDA supply.
- Contract sterile manufacturing plays a key role for availability.
Europe
- European GMP capacity supports both EU distribution and supply to US via ANDA programs.
Asia
- API synthesis and some finished-dose manufacturing scale heavily in Asia, with export to Western markets subject to GMP and quality agreements.
How do you identify ertapenem sodium suppliers by NDC and ANDA?
Featured snippet answer: Use FDA’s NDC/labeler mapping and the Orange Book to link products to ANDA holders and then map the label’s “manufactured for” lines to find real-world suppliers.
Practical workflow used in procurement and competitive intelligence
- Identify target strength and dosage form (commonly vial for IV use).
- Pull the Orange Book listing for that strength/form to identify the ANDA holder.
- Pull the package insert/label to capture the manufacturing site.
- Identify repeat labels across multiple NDCs for supplier clustering.
What supplier risks drive ertapenem sodium shortages?
Featured snippet answer: Shortages and allocation risk are driven by sterile manufacturing capacity, beta-lactam process disruptions, and batch yield or QC failures.
Supplier failure modes
- Lyophilization cycle disruptions or QC OOS rates
- Sterile filter issues during formulation and fill
- API intermediate supply constraints
- Transport and reconstitution stability constraints affecting batch release
Do biosimilar or follow-on biologics issues affect ertapenem sodium supply?
Featured snippet answer: No. Ertapenem sodium is a small-molecule antibiotic, not a biologic. The supply and exclusivity framework is handled through ANDAs/generics rather than biosimilars.
How do exclusivity and patent status affect who can supply ertapenem sodium?
Featured snippet answer: Patent expiry and regulatory exclusivity affect which ANDA filers can launch without risk of infringement. Supply expands after key exclusivity windows end, typically with multiple ANDA entrants and increased distributor availability.
Where supplier count typically rises
- After composition-of-matter and key formulation/manufacturing method patents expire.
- After any regulatory exclusivity (product-specific) ends, allowing FDA approvals and commercial launches.
Key procurement-ready supplier shortlist template for ertapenem sodium
Featured snippet answer: A usable supplier list should be built from: (i) API manufacturer(s), (ii) finished-dose manufacturer(s), and (iii) ANDA holders/labelers for the exact NDCs in your formulary.
Supplier shortlist format
| Layer |
Supplier type |
What to capture |
Best public source |
| API |
API manufacturer |
GMP site, product grade, DMF/CEP link if available |
regulatory dossiers, DMF references |
| Finished dose |
Sterile/lyophilized manufacturer |
manufacturing site, vial count, fill-finish capability |
package insert label |
| ANDA/labeler |
ANDA holder |
US applicant, brand/market authorization |
Orange Book + label |
| Distribution |
wholesaler |
contract terms, allocation history |
procurement history |
What can procurement teams do to validate ertapenem sodium suppliers quickly?
Featured snippet answer: Validate suppliers by matching three identifiers: NDC, labeler/manufacturer, and manufacturing site.
Validation checklist
- NDC-to-labeler mapping
- Manufacturing site on carton/insert
- Lot release documentation and QC method consistency
- Supply continuity and past allocation events
Key Takeaways
- Ertapenem sodium supply is concentrated across a limited number of global API and finished-dose manufacturers.
- “Suppliers” should be defined by supply-chain tier (API vs finished sterile vials vs labeler/ANDA holder vs distributor).
- The fastest accurate mapping for procurement is via Orange Book + label manufacturing lines, tied to the exact strength/dosage form/NDC.
- Shortage risk is driven primarily by sterile manufacturing capacity and beta-lactam process constraints, not biologic pathways.
FAQs
1) How do I find the manufacturer of ertapenem sodium vials for a specific NDC?
Use the NDC on the package to pull the label/insert, then capture the “manufactured for” line and manufacturing site from the insert.
2) Which US ANDA holders sell ertapenem sodium injection?
Use FDA Orange Book listings for ertapenem sodium injection by strength/dosage form to identify ANDA applicants tied to specific NDCs.
3) What indicates API supply continuity risk for ertapenem sodium?
Track sterile fill-finish batch yield, QC OOS frequency, and API intermediate supply disruptions that show up in availability patterns and allocation notices.
4) Do generic ertapenem sodium products use the same API suppliers?
Often multiple ANDA programs can source from overlapping API manufacturers, but label/manufacturer mapping is the practical way to confirm linkage for a given NDC.
5) What are the main manufacturing steps that constrain ertapenem sodium supply?
API synthesis, formulation, sterile filtration/fill, and lyophilization (if supplied as a lyophilized vial) are the steps most likely to constrain throughput and batch release.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (ertapenem sodium listings).
- FDA NDC Directory (labeler and product mapping by NDC).
- FDA prescribing information and carton labeling for ertapenem sodium injection products (manufacturer lines and manufacturing sites).
